Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Weekly News Recap #Phispers
1. Irbinitinib
2. N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-n4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine
3. N6-(4,5-dihydro-4,4-dmethyl-2-oxazolyl)-n4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-4,6-quinazolinediamine
4. Ont-380
5. Tukysa
1. Irbinitinib
2. 937263-43-9
3. Ont-380
4. Tukysa
5. 6-diamine
6. N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-n4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine
7. 234248d0hh
8. Irbinitinib; Arry-380; Ont-380
9. 4,6-quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-n4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-
10. N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-n6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine
11. N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-n4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine
12. Tucatinib [inn]
13. 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine
14. Unii-234248d0hh
15. Ont 380
16. Tukysa (tn)
17. Ont-380;tucatinib
18. Tucatinib [mi]
19. Tucatinib (usan/inn)
20. Tucatinib [usan:inn]
21. Tucatinib [usan]
22. Irbinitinib(arry-380)
23. Irbinitinib; Arry-380
24. Tucatinib [who-dd]
25. Gtpl9922
26. Schembl1193050
27. Tucatinib [orange Book]
28. Chembl3989868
29. Bdbm471617
30. Dtxsid601027958
31. Bcp15983
32. Ex-a1031
33. Mfcd22380467
34. Nsc764581
35. Nsc799335
36. S8362
37. Zinc68250462
38. Arry-380 (ont-380)
39. Akos026750449
40. Ccg-264747
41. Cs-3906
42. Db11652
43. Nsc-764581
44. Nsc-799335
45. Sb17126
46. Us10822334, Compound Ont380
47. Ncgc00482879-02
48. Ac-33037
49. As-56109
50. Bt177688
51. Hy-16069
52. Example 11 [wo2007059257a2]
53. Db-130430
54. A16413
55. D11141
56. A857335
57. Q25100690
58. 4,6-quinazolinediamine,n6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-n4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-
59. N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-n4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine;
60. N6-(4,5-dihydro-4,4-dmethyl-2-oxazolyl)-n4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-4,6-quinazolinediamine
Molecular Weight | 480.5 g/mol |
---|---|
Molecular Formula | C26H24N8O2 |
XLogP3 | 4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 6 |
Exact Mass | 480.20222204 g/mol |
Monoisotopic Mass | 480.20222204 g/mol |
Topological Polar Surface Area | 111 Ų |
Heavy Atom Count | 36 |
Formal Charge | 0 |
Complexity | 796 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Tucatinib is indicated with trastuzumab and capecitabine for treatment of adults diagnosed with advanced unresectable or metastatic HER2-positive breast cancer. This includes patients with brain metastases and those who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2positive locally advanced or metastatic breast cancer who have received at least 2 prior antiHER2 treatment regimens.
By inhibiting tyrosine kinase, tucatinib exerts anti-tumor activity, reducing the size of HER-2 positive breast cancer tumors. In clinical trials, the regimen of tucatinib and [trastuzumab] showed enhanced activity both in vitro and in vivo when compared to either drug administered by itself.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
L01
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01E - Protein kinase inhibitors
L01EH - Human epidermal growth factor receptor 2 (her2) tyrosine kinase inhibitors
L01EH03 - Tucatinib
Absorption
The Tmax for tucatinib ranges from 1 to 4 hours. One pharmacokinetic study revealed a Cmax of 1120 ng/mL after a dose of 350 mg twice daily with a Tmax ranging from 1 to 3 hours. The AUCtau was reported to be about 7120 hoursng/mL.
Route of Elimination
In a study of radiolabled tucatinib, about 86% of the total dose was excreted in the feces and 4.1% was found in the urine. About 16% of the tucatinib dose recovered in the feces was identified as unchanged tucatinib.
Volume of Distribution
The volume of distribution of tucatinib is about 1670 L. This drug penetrates the blood-brain barrier.
Clearance
The apparent clearance is 148 L/h.
Tucatinib is metabolized by CYP2C8 with some contributions from CYP3A.
A pharmacokinetic study revealed a half-life of approximately 5.38 hours. Prescribing information mentions a geometric mean half-life of about 8.21 hours.
Mutations in the HER-2 gene are observed in some types of breast carcinoma. Tucatinib inhibits the tyrosine kinase enzyme of the HER-2 gene. Mutations of tyrosine kinase in the HER-2 gene lead to cascade effects of increased cell signaling and proliferation, resulting in malignancy. Results of in vitro studies show that tucatinib inhibits the phosphorylation of both HER-2 and HER-3, leading to downstream changes in MAPK and AKT signaling and cell proliferation. Anti-tumor activity occured in the cells that expressed HER-2. In vivo, tucatinib has been shown to inhibit HER-2 expressing tumors, likely by the same mechanism.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Tucatinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tucatinib, including repackagers and relabelers. The FDA regulates Tucatinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tucatinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tucatinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tucatinib supplier is an individual or a company that provides Tucatinib active pharmaceutical ingredient (API) or Tucatinib finished formulations upon request. The Tucatinib suppliers may include Tucatinib API manufacturers, exporters, distributors and traders.
click here to find a list of Tucatinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tucatinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Tucatinib active pharmaceutical ingredient (API) in detail. Different forms of Tucatinib DMFs exist exist since differing nations have different regulations, such as Tucatinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tucatinib DMF submitted to regulatory agencies in the US is known as a USDMF. Tucatinib USDMF includes data on Tucatinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tucatinib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tucatinib suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Tucatinib Drug Master File in Korea (Tucatinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Tucatinib. The MFDS reviews the Tucatinib KDMF as part of the drug registration process and uses the information provided in the Tucatinib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Tucatinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Tucatinib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Tucatinib suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tucatinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tucatinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tucatinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tucatinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tucatinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tucatinib suppliers with NDC on PharmaCompass.
Tucatinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tucatinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tucatinib GMP manufacturer or Tucatinib GMP API supplier for your needs.
A Tucatinib CoA (Certificate of Analysis) is a formal document that attests to Tucatinib's compliance with Tucatinib specifications and serves as a tool for batch-level quality control.
Tucatinib CoA mostly includes findings from lab analyses of a specific batch. For each Tucatinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tucatinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Tucatinib EP), Tucatinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tucatinib USP).
LOOKING FOR A SUPPLIER?